Basic Information

Gene symbol CSF2 Synonyms CSF, GMCSF Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas
Description colony stimulating factor 2


GTO ID GTC4001
Trial ID NCT03003676
Disease Melanoma
Altered gene E1A|CSF2
Therapeutic/Target gene Therapeutic gene
TherapyDNA oncolytic virus
Treatment ONCOS-102|CGTG-102
Co-treatment Cyclophosphamide|Pembrolizumab
PhasePhase1
Recruitment statusCompleted
TitleA Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After PD1 Blockade
Year2016
CountryUnited States|Norway
Company sponsorTargovax Oy
Other ID(s)ONCOS C824
Vector information
Vectoradenovirus
ConstructAd5/3-delta24-GMCSF
Vector typeserotype 5 adenovirus
Transgene/Inserted geneGM-CSF, which enhances antitumor immunity by recruiting antigen-presenting cells (APCs) and natural killer (NK) cells, activates and matures APCs at the tumor site, thereby potentiating the ability of ONCOS-102 to induce cellular immunity against the tumor in which it replicates.
Viral genome modificationONCOS-102 has a genetically modified fiber with a serotype 3 knob for enhanced gene delivery to cancer cells. A 24-bp deletion has been made in the Rb binding site of the E1A gene.
Additional featureGM-CSF

Clinical Result

Cohort1: ONCOS-102_days 1, 4, and 8
Administration route intratumoral injection|intravenous infusion
Dosage ONCOS-102, 3 doses, 3E11 viral particles (VP), days 1, 4, and 8|cyclophosphamide, 1-3 days prior to day 1|pembrolizumab, 2mg/kg, on day 22 (Week 3) and every 3 weeks thereafter until the end of treatment visit on day 169 (Week 24)
Pts 9
Age Adult, Older_Adult
Adverse reactions 0/9(All-cause mortality); 4/9(Blood and lymphatic system disorders; Gastrointestinal disorders; Infections and infestations; Metabolism and nutrition disorders; Musculoskeletal and connective tissue disorders; Respiratory, thoracic and mediastinal disorders)
References PMID: 30713786
Cohort2: ONCOS-102_days 1, 4, 8 and 15
Administration route intratumoral injection|intravenous infusion
Dosage ONCOS-102, 4 doses, 3E11 viral particles (VP), days 1, 4, 8 and 15|cyclophosphamide, 1-3 days prior to day 1|pembrolizumab, 2mg/kg, starting on Day 22/Week 3 and every three weeks thereafter until Day 169/Week 24 or until unacceptable toxicity
Pts 12
Age Adult, Older_Adult
Adverse reactions 0/12(All-cause mortality); 2/12(Gastrointestinal disorders; General disorders; Nervous system disorders; Respiratory, thoracic and mediastinal disorders)
References PMID: 30713786

Relationship Graph

Overview of Knowledge Graph